LANCANG TEA(06911): Wang Juan is appointed as a non-executive director
Lancang Ancient Tea (06911) announced that Ms. Wang Juan has resigned from the board of directors on January 5, 2025 due to personal health reasons.
LANCANG TEA (06911) announced that Ms. Wang Juan has submitted a written resignation to the board of directors on January 5, 2025 due to personal health reasons. As a result, she has decided to resign from her positions as a member of the board of directors' Remuneration and Assessment Committee, a member of the board of directors' Strategic Committee, and the company's general manager, effective from January 5, 2025.
In light of Ms. Wang Juan's resignation from the position of general manager, the board of directors resolved on January 6, 2025 to appoint her as a non-executive director; and to elect Ms. Du Chunyi, the chairman and executive director of the company, as the interim acting general manager, effective from the date of the board's approval until the appointment of a new general manager.
The board of directors resolved on January 6, 2025 to elect Mr. Liu Jiajie, an executive director, as a member of the board of directors' Strategic Committee; and Dr. Yang Kequan, an independent non-executive director, as a member of the board of directors' Remuneration and Assessment Committee, effective from January 6, 2025.
Dr. Xie Xiaoyao has submitted a written resignation to the board of directors on January 4, 2025 due to other work arrangements. As a result, he has decided to resign from his positions as an independent non-executive director of the company, chairman of the board of directors' Remuneration and Assessment Committee, chairman of the board of directors' Nomination Committee, and a member of the board of directors' Audit Committee.
Related Articles

The entire market is chasing AI, while "big short" Burry is going against the trend and buying low: Adobe, Alibaba, and four other stocks are favored.

Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?

New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.
The entire market is chasing AI, while "big short" Burry is going against the trend and buying low: Adobe, Alibaba, and four other stocks are favored.

Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?

New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.

RECOMMEND





